Product
Placebo Cagrilintide
1 clinical trial
1 indication
Indication
ObesityClinical trial
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or ObesityStatus: Recruiting, Estimated PCD: 2025-02-18